购物车
- 全部删除
- 您的购物车当前为空
TLR7/8/9 antagonist 2 是一种具有口服活性和较高生物利用度的 vTLR7/8/9 拮抗剂。TLR7/8/9 antagonist 2 对 HEK/hTLR7、HEK/hTLR8 和 HEK/hTLR9 具有抑制作用,IC50 分别为 0.011 μM、0.029 μM 和 0,052 μM。TLR7/8/9 antagonist 2 可用于研究系统性红斑狼疮或狼疮性肾炎等自身炎症性疾病。
TLR7/8/9 antagonist 2 是一种具有口服活性和较高生物利用度的 vTLR7/8/9 拮抗剂。TLR7/8/9 antagonist 2 对 HEK/hTLR7、HEK/hTLR8 和 HEK/hTLR9 具有抑制作用,IC50 分别为 0.011 μM、0.029 μM 和 0,052 μM。TLR7/8/9 antagonist 2 可用于研究系统性红斑狼疮或狼疮性肾炎等自身炎症性疾病。
产品描述 | TLR7/8/9 antagonist 2 is an orally active and highly bioavailable vTLR7/8/9 antagonist. TLR7/8/9 antagonist 2 inhibits HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50s of 0.011 μM, 0.029 μM and 0,052 μM, respectively. TLR7/8/9 antagonist 2 can be used to study auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis. |
靶点活性 | HEK/hTLR9:0.052 μM, HEK/hTLR7:0.011 μM, HEK/hTLR8:0.029 μM |
体外活性 | TLR7/8/9 antagonist 2 exhibited inhibitory activity against HEK/hTLR7, HEK/hTLR8, and HEK/hTLR9 with IC50 values of 0.011 μM, 0.029 μM, and 0,052 μM, respectively.[1] TLR7/8/9 antagonist 2 showed inhibitory activity against hPBMC/TLR9 with an IC50 value of 420 nM.[1] |
体内活性 | TLR7/8/9 antagonist 2 has a high in vivo bioavailability.[1] |
分子量 | 405.54 |
分子式 | C23H31N7 |
CAS No. | 2920729-91-3 |
密度 | no data available |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容